NR3C1 and Duchenne muscular dystrophy: New glucocorticoid derivatives such as vamorolone, currently in trial for Duchenne muscular dystrophy (NCT03439670), will likely offer new insights, although the time-dependent pharmacology for vamorolone will likely be very different from the mechanisms reported here as this drug minimizes the GR transactivation activity (40).